pCDCAR1 GD2 h(4γ), T(CAR-T-2-M326-4G)
The vector of anti-GD2 chimeric antigen receptor(CAR) is constructed for the engineering of T cells to target Human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GD2 antibody linked to CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the treatment of neuroblastoma.
Targeting Cell Type
Discription of Signaling Cassetes
Cluster of Differentiation 4 (CD4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages and dendritic cells, and plays an important role in the development and activation of T cells. On T cells, CD4 is the co-receptor for the T cell receptor (TCR), and these two distinct structures recognize the Antigen-Major Histocompatibility Complex (MHC). CD4 signaling in CAR ensures specificity of the TCR-antigen interaction, prolongs the contact between the T cell and the antigen presenting cell and recruits the tyrosine kinase Lck, which is essential for T cell activation.
The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.
beta-1,4-N-acetyl-galactosaminyl transferase 1
B4GALNT1; beta-1,4-N-acetyl-galactosaminyl transferase 1; disialoganglioside; GALGT; SPG26; GALNACT; GalNAc-T; scFv; FcεRIγ; Chimeric antigen receptor; NK cell; Retrovirus; CARs; Lentivirus; chimeric NK cell receptors; chimeric immunoreceptors; chimeric antigen receptors; ch14.18
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Lenti-GD2 CAR (scFv-CD4-FcεRIγ, ch14.18) Viral Particle
||Lenti-GD2 CAR (scFv-CD8-CD3ζ, ch14.18) Viral Particle
||Anti-GD2 scFv h(CD28) CARNK, pCDCAR1
||Anti-GD2 scFv h(CD8-CD3ζ) CART, pCDCAR1
||Anti-GD2 scFv h(CD28-CD3ζ) CARNK, pCDCAR1
||Lenti-GD2 CAR (scFv-CD4-CD3ζ, ch14.18) Viral Particle
||Anti-GD2 scFv h(CD4-CD3ζ) CARNK, pCDCAR1
||Anti-GD2 scFv h(FcεRIγ) CART, pCDCAR1
||Lenti-GD2 CAR (scFv-b2c-CD3ζ, ch14.18) Viral Particle
||Anti-GD2 scFv h(41BB-CD3ζ) CARNK, pCDCAR1
||Lenti-GD2 CAR (scFv-CD28-41BB-CD3ζ, ch14.18) Viral Particle
||Anti-GD2 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1
||Lenti-GD2 CAR (scFv-FcεRIγ, ch14.18) Viral Particle
||Anti-GD2 scFv h(CD4-CD3ζ) CART, pCDCAR1
||Anti-GD2 scFv h(41BB-CD3ζ) CART, pCDCAR1
||Anti-GD2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1
||Anti-GD2 scFv h(b2c-CD3ζ) CART, pCDCAR1
||Anti-GD2 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1
||Lenti-GD2 CAR (scFv-CD28-FcεRIγ, ch14.18) Viral Particle
||Lenti-GD2 CAR (scFv-CD3ζ, ch14.18) Viral Particle